No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Marksans Pharma Limited, along with its associated entities, operates globally in the pharmaceutical sector, focusing on the entire lifecycle of generic medications, from their initial research and development to manufacturing, marketing, and ultimate sale. Its extensive product range addresses a wide spectrum of health conditions and therapeutic areas. These encompass pain management (analgesics, anti-inflammatory), diabetes, neurological disorders (epilepsy, neurology), cardiovascular health, hormonal treatments, oncology, gastrointestinal issues (gastroenterology, antacids, antiulceratives), benign prostatic hyperplasia, hyperparathyroidism, gynecology, antifungal and antibacterial applications, anti-allergy, vitamin supplements, dermatology, cephalosporins, and hypertension, also including injectable formulations. The company was established in 1992 and maintains its headquarters in Mumbai, India.
marksanspharma.comNo one on the platform currently holds MARKSANS.BO.
No tracked institution reports a position in MARKSANS.BO as of their last filing.
No one on the platform has traded MARKSANS.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.8% | 24.5% | 22.9% | — | — | — |
| Rev. Growth % | 12.5% | 16.6% | ||||
| Profit Margin % | 14.2% | 14.0% | 11.1% | |||
| Free Cash Flow Margin % | 11.9% | 5.5% | 5.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $35.7B | +23.1% | $12.55 | $10.93–$13.60 | — | 2 |
| 2028 | $41.1B | +15.1% | $15.25 | $12.68–$16.70 | — | 3 |
| 2029 | $48.3B | +17.6% | $18.40 | $17.80–$18.84 | — | 1 |
| 2030 | $58.2B | +20.5% | $20.40 | $19.73–$20.89 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $3.30 | $3.45 | +4.5% |
| 2026-02-05 | $2.40 | $2.50 | +4.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MARKSANS.BOMarksans Pharma Limited | $312.40 | -4.84% | $141.6B | — |
| AARTIPHARM.BOAarti Pharmalabs Limited | $789.30 | -4.55% | $71.2B | — |
| AARTIPHARM.NSAarti Pharmalabs Limited | $789.45 | -4.53% | $71.6B | — |
| FDC.BOFDC Limited | $349.35 | +2.15% | $56.8B | — |
| FDC.NSFDC Limited |
| $349.65 |
| +2.40% |
| $56.9B |
| — |
| SANOFI.BOSanofi India Limited | $3130.25 | +1.63% | $72.1B | — |
| SANOFI.NSSanofi India Limited | $3131.90 | +1.71% | $72.1B | — |
Source: Financial Modeling Prep · peers by sector/industry